An Era Concludes: CureVac’s Stock Market Journey Ends Following BioNTech Acquisition

The independent public listing of Tübingen-based mRNA pioneer CureVac has been formally terminated. The company’s shares have been delisted from exchanges, marking the final chapter in its standalone history, after competitor BioNTech completed a full acquisition. For former shareholders, a critical deadline is now imminent: the final opportunity to reclaim Dutch withholding tax expires today, January 27, 2026.

Integration and Delisting Details

BioNTech’s takeover was formally concluded on January 6, 2026, following a completed restructuring. This move granted BioNTech sole ownership of all business operations. The former CureVac SE entity was replaced by its legal successor, CureVac Merger B.V., a step that finalized the delisting process.

Key transaction metrics highlight the scale of this corporate integration:
* Equity Value: Approximately $1.25 billion
* Tendered Shares: 86.75% of the issued capital
* Trading Halt: January 6, 2026
* Official Delisting: Effective January 16, 2026

With the investment vehicle dissolved, former CureVac investors who did not sell their holdings now hold a direct stake in BioNTech’s corporate performance. Any future progress or setbacks stemming from the Tübingen technology platform will be reflected solely in the financial statements and share price of the Mainz-based parent company.

Should investors sell immediately? Or is it worth buying CureVac?

Urgent Tax Reclaim Deadline for Shareholders

Minority shareholders who did not participate in the initial exchange offer face a crucial deadline today. Dutch dividend withholding tax was applied to the compensation paid during the squeeze-out procedure. Although the statutory rate is 15%, an effective rate of 3.01% was implemented due to the transaction’s specific structure.

Shareholders residing outside the Netherlands must submit their reclaim application directly to BioNTech via email before the day ends. Missing this cutoff will result in the permanent forfeiture of any refund claims. It is noted that any applicable bank charges will be deducted directly from the reimbursement amount.

Scientific Legacy Continues Within BioNTech

While CureVac’s stock is no longer traded, its scientific assets and research continue. The entire research and development pipeline has been integrated into BioNTech’s infrastructure. This transfer includes not only mRNA design expertise and manufacturing capabilities but also specific clinical programs, such as an FDA-approved immunotherapy project targeting lung cancer.

The situation for investors is now clear. The standalone entity CureVac has ceased to exist, with its innovative work set to advance under the BioNTech umbrella.